WATCHLONGEVITY

Monday, May 4, 2026

DEVELOPING
UPDATE45
DEALLimited grounding

HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business - The Manila Times

HYTN is planning to separate its BPC-157 peptide drug business into its own company. BPC-157 is an experimental peptide drug being tested for various medical uses.

Analysis

HYTN's proposed spin-out isolates BPC-157 development into a standalone vehicle, a structural move that could unlock dedicated financing for an experimental peptide asset.

  • HYTN announced a proposed spin-out of its BPC-157 peptide drug development business
  • BPC-157 is an experimental peptide being tested for multiple medical uses
bpc-157HYTN
Peptide Therapy Research10d
Read
UPDATE35
DEALLimited grounding

HYTN plans separate BPC-157 drug company, targets $1M raise - Stock Titan

A company called HYTN is creating a separate business focused on developing BPC-157 (a peptide used in research) and is trying to raise $1 million for it. This move splits the BPC-157 work into its own independent company.

Analysis

HYTN spinning out a BPC-157 venture with a $1M raise signals continued micro-cap interest in research peptides, but the size makes it noise for institutional investors.

  • HYTN plans separate company focused on BPC-157
  • Targets $1 million raise for the new entity
  • BPC-157 program will be split into its own independent company
bpc-157HYTN
Peptide Therapy Research10d
Read